Aurobin, ointment 20 g

Anal itching, Anal fissures, Skin lesions, HemorrhoidsProcesses accompanied by perianal inflammation, anal itching, eczema and dermatitis of the perianal area, fissures, hemorrhoids, anal fistula.

Active ingredient

Dexpanthenol, Prednisolone, Lidocaine

Composition

1 g ointment contains:

the active ingredients:

prednisolone capronate 2 mg,

lidocaine hydrochloride 20 mg,

D-panthenol 20 mg;

excipients:

Polysorbate 60,

Triclosan,

Methylparahydroxybenzoate, <

cetyl alcohol,

glycerol,

propylene glycol,

macrogoal stearate,

liquid paraffin,

dimethicone,

p> neutral oil,

stearic acid,

purified water.

How to take, the dosage

Outwardly, rectally.

Adults, elderly patients: Apply the ointment to the affected surface 2-4 times a day.

For internal hemorrhoids, a small amount of ointment (the size of a pea) is inserted into the rectum 2-4 times a day. When the symptoms are reduced the drug can be used less frequently. The course of treatment is 5-7 days.

Children under 12 months should not use the ointment.

When using the drug in children, avoid prolonged use on a large surface area regardless of age.

Interaction

No drug interactions are known when the drug is used topically.

Special Instructions

Long-term therapy should be avoided if possible, especially in children, because of possible suppression of adrenal function. In children the drug can be used with caution, in the minimum dose to achieve the therapeutic effect. The duration of therapy in children should not exceed 5 days.

Any accidental contact with the eye or periorbital area should be avoided.

In case of contact, flush with water.

The development or spread of a secondary infection requires discontinuation of the drug and administration of antimicrobial or antifungal therapy. Bacterial infection is sustained in warm moist conditions, so the skin should be cleaned before each application of the ointment.

Application over a large surface area or use over a long period of time may lead to systemic absorption of the active ingredients. Prolonged use in one area may cause skin atrophy, especially in younger individuals.

The drug’s effect on driving and operating machinery

There are no data on the effect of Aurobin® affecting driving ability or working in high attention environments.

Contraindications

• High sensitivity to the components of the drug.
• The drug should not be used to treat the eyes or periorbital area.
• Bacterial, viral or fungal skin infections.
• Simultaneous use of lidocaine for other indications.
• Children under 1 year.

.

Side effects

The use of topical glucocorticosteroids may primarily cause local side effects: impaired wound healing, burning sensation, itching, irritation, dryness, thinning of the skin, increased skin sensitivity.

With long-term use of glucocorticosteroids – skin atrophy, local hirsutism, telangiectasia, purpura, hypopigmentation, hypertrichosis, folliculitis, acne-like eruptions, development of fungal infection, allergic contact dermatitis, diaper rash.

When applied to large surfaces – systemic side effects of glucocorticosteroid (growth retardation, icenko-Cushing’s syndrome, benign increase of intracranial pressure after treatment completion, hyperglycemia, glucosuria, hypokalemia, increased arterial pressure).

During prolonged use and on a large surface due to the systemic action of lidocaine bradycardia may occur.

Overdose

Acute overdose is unlikely; however, in chronic overdose or improper use of the drug, symptoms may occur due to systemic action of the glucocorticosteroid, as well as bradycardia if the drug is injected excessively into the rectum (due to lidocaine) and treatment should be stopped or the dose gradually reduced.

Pregnancy use

There are no data on safety and efficacy of the drug administration in pregnancy, therefore it is not recommended to prescribe Aurobin in the first trimester of pregnancy.

In the second and third trimesters of pregnancy, if it is necessary to use the drug, the estimated benefit to the mother and the potential risk to the fetus should be weighed.

Breast-feeding period: corticosteroids and lidocaine penetrate the mother’s milk, so if the drug has to be used during lactation, consideration should be given to stopping breast-feeding.